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ABSTRACT
Background
Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell,
endometrioid, and mucinous) are associated with different natural histories, most ovarian
carcinoma biomarker studies and current treatment protocols for women with this disease are
not subtype specific. With the emergence of high-throughput molecular techniques, distinct
pathogenetic pathways have been identified in these subtypes. We examined variation in
biomarker expression rates between subtypes, and how this influences correlations between
biomarker expression and stage at diagnosis or prognosis.
Methods and Findings
In this retrospective study we assessed the protein expression of 21 candidate tissue-based
biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1,
Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-
based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000.
The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not
vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers
are prognostic indicators in the entire cohort but when analyzed by subtype only three remain
prognostic indicators in the high-grade serous and none in the clear cell subtype. For example,
tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes
and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95%
confidence interval [CI] 1.2%–2.4%) but is not of prognostic significance within any subtype.
Prognostic associations can even show an inverse correlation within the entire cohort, when
compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade
serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the
entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%–2.3%), but is a favourable prognostic
marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%–0.8%).
Conclusions
The association of biomarker expression with survival varies substantially between subtypes,
and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype
within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different
diseases, and these differences should be reflected in clinical research study design and
ultimately in the management of ovarian carcinoma.
The Editors’ Summary of this article follows the references.
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Ovarian carcinoma is a heterogeneous disease. On the basis
of histopathological examination, pathologists classify ovar-
ian carcinoma into serous, clear cell, endometrioid, and
mucinous subtypes. Each of theses subtypes is associated with
different genetic risk factors and molecular events during
oncogenesis [1,2], and characterized by distinct mRNA
expression proﬁles [3,4]. These subtypes differ dramatically
in frequency, when early stage carcinomas (where the
majority are nonserous carcinomas [5]) and advanced stage
carcinomas (which are predominantly of serous subtype [6])
are compared.
Oncologists have noted that subtypes respond differently
to chemotherapy. The dismal response rate of clear cell
carcinomas (15%) contrasts sharply with that of high-grade
serous (80%), resulting in a lower 5-y survival for clear cell
compared with high-grade serous carcinoma in patients with
advanced stage tumors (20% versus 30%) [7,8]. Therefore, the
National Cancer Institute (NCI) State of Science meeting
recently singled out clear cell carcinoma as a candidate for
clinical trials to identify more active therapy than what is
currently available [9]. Although these data suggest substan-
tial differences between subtypes, ovarian carcinoma is
typically approached as a monolithic entity by researchers
and clinicians. This practice impedes progress in under-
standing the biology or improving the management of the less
common ovarian carcinoma subtypes.
We hypothesized that correlations between biomarker
expression and stage at diagnosis or prognosis would reﬂect
subtype variation in biomarker expression. To test this
hypothesis we correlated protein expression rates of a panel
of 21 candidate biomarkers with stage at diagnosis and
disease-speciﬁc survival (DSS) in a large cohort of ovarian
carcinomas and also analyzed these associations within
ovarian carcinoma subtypes.
Methods
Study Population
The Cheryl Brown Ovarian Cancer Outcomes Unit is an
ovarian cancer registry serving a population of approxi-
mately four million people in British Columbia. For the
period 1984–2000, 2,555 patients with ovarian carcinoma
were recorded in the registry. From these 834 patients were
selected based on the criterion being free of macroscopic
apparent residual disease after primary surgery and all
histological slides underwent gynecopathological review.
Subtypes were assigned according to reﬁned World Health
Organization (WHO) criteria [10] as recently described [5]. A
further 91 patients diagnosed in stage 1a or 1b, grade 1 were
excluded from the study because of excellent prognosis; only
3% of women in this group died of disease during the follow-
up period. From the remaining patients 541 tissue blocks
were available and used for tissue microarray (TMA)
construction. A representative area of each tumor was
selected and duplicate 0.6-mm tissue cores were punched to
construct a TMA (Beecher Instruments). Review after TMA
construction revealed that 23 cases were not adequately
sampled. Of these 23 cases, 20 mixed carcinomas (.10% of
tumor showing a second histological cell type) were excluded
because their highest grade component was not sampled on
the TMA; 18 cases were either of rare histological types
(including seven undifferentiated, six transitional, and one
squamous carcinoma) or could not be speciﬁed (ﬁve cases).
This approach resulted in a study population of exactly 500
cases belonging to one of the four major cell types (serous,
endometrioid, clear cell, and mucinous) (Table 1). The serous
subtype was further subdivided into low- and high-grade [11].
Two cases of endometrioid carcinomas containing minor
mucinous or low-grade serous components (.10%) are
included in the study.
Adjuvant Therapy and Follow-up
All patients received standardized treatment according to
the provincial treatment guidelines of the British Columbia
Cancer Agency (BCCA) [12,13]; however, 3% of patients
refused the advised adjuvant chemotherapy and were excluded
from survival analysis. For 3% adjuvant therapy was not
advised, hence 94% received platinum-based chemotherapy
(with or without abdomino-pelvic radiotherapy) adjuvant
treatments. Outcomes were tracked via the Cheryl Brown
Ovarian Cancer Outcomes Unit at the BCCA and were
available for all patients. Follow-up information was obtained
Table 1. Study Population
Clinical Variable Numerical Display All High-Grade Serous Clear Cell Endometrioid Mucinous Low-Grade Serous
Number of cases n 500 200 132 125 31 12
Proportion % 100 40.0 26.4 25.0 6.2 2.4
Age in years Mean 6 SE 58.1 6 0.6 60.9 6 0.8 56.2 6 1.1 56.0 6 1.2 55.4 6 2.4 60.2 6 4.1
Follow-up time in years Mean 6 SE 5.9 6 0.2 5.4 6 0.2 6.3 6 0.4 6.4 6 0.3 5.4 6 0.7 5.8 6 1.1
Death n (%) 233 (46.6) 124 (62.0) 52 (39.4) 39 (31.2) 11 (35.5) 7 (58.3)
Death of disease n (%) 164 (32.8) 92 (46.0) 40 (30.3) 19 (15.2) 8 (25.8) 5 (41.7)
10 YSR DSS % 6 SE 57.8 6 2.9 38.9 6 4.7 63.7 6 5.2 83.9 6 4.2 72.0 6 10.0 48.0 6 19.1
Stage I n (%) 205 (41.0) 49 (24.5) 68 (51.5) 69 (55.2) 18 (58.1) 1 (8.3)
Stage II n (%) 211 (42.2) 86 (43.0) 56 (42.4) 50 (40.0) 12 (38.7) 7 (58.3)
Stage III n (%) 84 (16.8) 65 (32.5) 8 (6.1) 6 (4.8) 1 (3.2) 3 (33.3)
Grade 1 n (%) 105 (21.0) 0 0 82 (65.6) 11 (35.5) 12 (100)
Grade 2 n (%) 109 (21.8) 56 (28.0) 0 35 (28.0) 18 (58.1) 0
Grade 3 n (%) 286 (57.2) 144 (72.0) 132 (100) 8 (6.4) 2 (6.5) 0
YSR DSS, year disease-specific survival rate; SE, standard error of the mean.
doi:10.1371/journal.pmed.0050232.t001
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patient’s paper chart. Examples of documentation used to
ascertain vital status include BCCA progress notes, death
certiﬁcates, and correspondence indicating status from other
care providers. Ovarian carcinoma speciﬁc death was deﬁned
where ovarian cancer was the primary or underlying cause of
death. Death from concurrent disease (i.e., second malignancy)
was coded as ‘‘died of other cause.’’ Death resulting from
toxicities relating to treatments for ovarian carcinoma was
coded as ‘‘died of toxicities.’’ Abstracted data were reviewed by
an experienced medical oncologist (K.S.). Median follow-up
time was 5.1 y. Approval for the study was obtained from the
Research Ethics Board of the University of British Columbia.
Marker Selection and Immunohistochemistry
The goal of our marker selection was to use proteins that
are consistently expressed in ovarian carcinomas and have
been reported as prognosticators (p53, p21, Ki-67, PR, WT1)
[14–19] or being developed as early detection markers in
ovarian carcinomas [20]. This approach biased our results
towards selection of markers mostly derived from and
expressed in high-grade serous subtype. Serial 4-lm sections
were cut for immunohistochemical (IHC) analysis and run
through an automated protocol including heat antigen
retrieval (Ventana System). The antibodies and suppliers are
listed in Table 2. Speciﬁcity was determined by using
appropriate positive controls, with omission of primary
antibody as a negative control.
Evaluation of Immunohistochemistry
One or more pathologists (MK, DNI, or AR) scored these
biomarkers after scanning with a BLISS scanner (Bacus
Laboratories/Olympus America). Except KISS1 [21] and p53
[22] where recently published cut-off points were used, all
markers were dichotomized into negative and positive cases
(cut-off values for positive versus negative for all markers
except Ki-67 are shown in Table S1). Ki-67 was assessed as a
continuous variable as a percentage of positive tumor cells
using automated image analysis software [23]. Prior to
analysis a pathologist (MK) manually selected regions of
interest so as to avoid noncancerous cellular areas. The
median was used to dichotomize into low- and high-
expressing groups for Ki-67.
Statistical Analysis
Contingency analysis and Pearson’s Chi
2 statistic were used
to test the change in the distribution of biomarker expression
across stage and subtypes. The Kruskal-Wallis test was used to
determine if Ki-67 was differentially expressed across stage
and subtypes. Univariable DSS was illustrated by the
generation of Kaplan-Meier curves and subgroup differences
tested with a univariable Cox model. Multivariable DSS was
tested using the Cox proportional hazards model. The Cox
proportional hazards model was used to determine risk ratios
(RRs) and p-values for all univariable and multivariable DSS
analyses. Additionally, to assess signiﬁcance in the presence of
some small subgroups, permutation tests were performed and
permutation p-values reported. Under the null hypothesis of
no association of biomarker status with survival (for survival
analyses) or stage/histology (for contingency table analyses),
the biomarker outcomes are exchangeable across cases. For
the survival analyses, permutations of biomarker outcomes
were performed within stage/subtype subgroups, to preserve
the observed distribution of biomarker frequencies within
Table 2. Antibodies
Number Biomarker Supplier Clone Dilution Full Name/Description
1 CA125 Cellmarque OC125 1:100 Cancer antigen 125, cell surface glycoprotein
2 CRABP-II Santa Cruz Polyclonal 1:25 Cellular retinoic acid-binding protein II, transcriptional regulator of lipid
metabolism
3 EpCam R&D Systems 158206 1:25 Epithelial cell adhesion molecule, cell-cell adhesion
4 ER Labvision SP1 1:200 Estrogen receptor
5 F-Spondin US Biological Polyclonal 1:50 Neuronal development
6 HE4 Signet Polyclonal 1:25 Human epididymis protein 4 is a member of 4-disulfide core protein with
unknown function
7 IGF2 Abcam Polyclonal 1:100 Insulin-like growth factor 2
8 K-Cadherin Abcam 2B6 1:50 Cell-cell adhesion protein
9 Ki-67 Labvision SP6 1:200 MKI, proliferation-associated antigen detected by Ki67
10 KISS1 Santa Cruz Polyclonal 1:400 Kisspeptins, ligands of G-protein coupled receptor 54
11 Matriptase Bethyl Polyclonal 1:25 Type II transmembrane trypsin-like serine protease, degradation of
extracellular matrix
12 Mesothelin Novocastra 5B2 1:50 Cell surface glycoprotein
13 MIF R&D Systems Polyclonal 1:2500 Macophage inhibitory factor, modulator of chronic inflammation
14 MMP7 Chemicon 141–7B2 1:200 Matrix metalloproteinase 7, degradation of extracellular matrix
15 p21 Labvision DCS-60.2 1:40 Cyclin-dependent kinase inhibitor 1A (Cip1)
16 p53 DAKO DO-7 1:400 Tumor protein p53
17 PAX8 Donation
a Polyclonal 1:500 Thyroid specific transcription factor, Pax8/PPARgamma fusion gene in 50%
of follicular thyroid carcinomas
18 PR Labvision SP2 1:400 Progesteron receptor
19 SLPI Hycult 31 1:100 Secretory leukocyte protease inhibitor
20 TROP2 R&D Systems Polyclonal 1:25 Tumor-associated calcium signal transducer 2
21 WT1 DAKO 6F-H2 1:100 Wilms tumor suppressor 1, zinc finger transcription factor
aThe a-mPax8-bIII antibody was kindly provided by Roberto Di Lauro, Stazione Zoologica, Naples, Italy.
doi:10.1371/journal.pmed.0050232.t002
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case’s entire biomarker panel at random without replacement
among cases, to preserve correlation structure within case. A
total of 10,000 permutation replications were performed. p-
Values were obtained by ﬁnding the number of permutation
sample estimates (Cox model parameter estimate for survival
analyses, Pearson Chi
2 statistic for contingency table analyses)
as extreme or more extreme than the observed value. p , 0.05
was considered statistically signiﬁcant. Hence, any prognostic
correlations for a single biomarker have to be interpreted
with caution. Statistical analyses were performed using SPSS
software (version 15.0; SPSS) and R (version 2.5.1; R
Foundation for Statistical Computing).
Results
Biomarker Expression Profile Reflects Subtype
This cohort of 500 ovarian carcinomas was mainly selected
based on the criterion of not having apparent residual tumor
after primary surgery. Since successful surgery is typically
achieved in lower stage, this case selection strategy can be
anticipated to include more cases of tumors of histological
subtypes that are commonly diagnosed at low stage, such as
clear cell carcinoma (26.4%), endometrioid (25.0%), and
mucinous (6.2%) carcinomas, although serous carcinomas
were still the most common subtype (40.0% high-grade and
2.4% low-grade) in this cohort (Table 1).
Interpretable results of immunostains for the 21 candidate
biomarkers (Figure 1) ranged from 363 to 493 (median 488,
Table S2). The larger numbers of missing data for three
biomarkers were caused by exhaustion of tumor material in
the core. All immunostains with annotated clinical informa-
tion are available online at http://www.gpecimage.ubc.ca
(username: BCCA-VGH; password: OVCARE). The rate of
positive cases for each biomarker ranged from 9% (KISS1) to
83% (EpCam) (detailed expression rates are listed in Table
S2). Comparing biomarker expression in the entire cohort for
tumors diagnosed at different stages revealed that ten
biomarkers (CRABP-II, ER, F-Spondin, K-Cadherin, Ki-67,
Matriptase, Mesothelin, p21, p53, and WT1) had signiﬁcantly
different expression levels between stages, suggesting differ-
ences between ‘‘early’’ and ‘‘late’’ stage disease (Figure 2,
Table S2). However, comparing biomarker expression within
one subtype across FIGO stages, no biomarker remained
signiﬁcantly differently expressed by stage (results for high-
grade serous subtype are shown in Figure 3). This result was
true for all four major subtypes (unpublished data for
endometrioid, clear cell, and mucinous). In contrast, 20 of
21 biomarkers were signiﬁcantly differentially expressed
between the subtypes (Figure 4). Only, EpCam (p ¼ 0.23)
showed a consistent expression frequency across all subtypes.
Additionally, p-values for biomarker expression rates in the
entire cohort across subtypes were generally smaller than
across stages (Table S2), indicating a stronger association with
subtype than stage.
High-grade serous carcinoma showed positive staining in
.75% of cases for WT1, Mesothelin, ER, and CA125 (Table
S2). The biomarker expression pattern of low-grade serous
carcinomas was similar to that of their high-grade counter-
parts. Three markers (PR, p53, K-Cadherin) showed a trend
towards differential expression in low-grade versus high-
grade serous subtypes. Only the median Ki-67 labelling index
differed signiﬁcantly between those groups, with median Ki-
67 labelling index of 2.5% (95% conﬁdence interval [CI]
0.5%–20.4%) in low-grade serous versus 22.4% (95% CI
3.6%–69.9%) in high-grade serous subtype (Figure 5).
Endometrioid carcinomas coexpress high rates of hormone
receptors ER and PR as well as CA125. Endometrioid and
clear cell subtypes infrequently (,10%) expressed WT1 and
p53. The median Ki-67 labelling index for endometrioid and
clear cell carcinomas was similar (endometrioid 8.2%, 95% CI
0.8%–49.0%; clear cell 7.6%, 95% CI 0.5%–45.0%). Immu-
nophenotypic characteristics of clear cell carcinomas in-
cluded low levels of hormone receptors ER (10%) and PR
(3%). The mucinous subtype displayed an intermediate
proliferative capacity compared with the other subtypes
(median Ki-67 labelling index 12.9%, 95% CI 2.1%–60.9%)
and frequent expression of Matriptase (86%). Many of the
markers expressed in other subtypes were either infrequently
(,10%) expressed (p53, ER, PAX8, SLPI, K-Cadherin, and
CA125), or completely absent (CRABP2, WT-1, and Meso-
thelin). Of note, EpCam was highly expressed across all
subtypes included in this study.
Survival Analyses Can Be Confounded by Subtype
Differences
To assess the biological importance of a biomarker, its
expression is usually correlated with outcome. Survival
analysis was restricted to the three major subtypes (high-
grade serous, clear cell, and endometrioid) because of
insufﬁcient numbers of cases of mucinous or low-grade
serous subtypes. The primary endpoint was deﬁned as DSS
and the rates after 10 y are shown for subtypes in Table 1. A
multivariable Cox regression model including age, stage, and
histological subtype showed signiﬁcant differences across
stage (p , 0.0001) and subtype (p ¼ 0.015). Survival by stage
showed little difference between stages I and II, with stage III
showing poorer DSS (RR 3.0, 95% CI 1.87%–4.66% relative to
stage I). Survival by subtype showed poorer DSS for clear cell
(RR 2.31, 95% CI 1.29%–4.15%) and high-grade serous (RR
2.74, 95% CI 1.56%–4.81%) relative to endometrioid subtype.
Age was not predictive in the model (p ¼ 0.211) (Table S3).
Univariable Cox regression analysis for each biomarker was
applied on the entire cohort as well as within the three largest
subtypes (Figure S1, Table 3). RRs and p-values are presented
in Table 3. Nine of 21 biomarkers show prognostic
signiﬁcance in the entire cohort. Of the nine biomarkers
showing a signiﬁcant association with DSS in the entire
cohort, three remain prognostic indicators in the high-grade
serous and one in the endometrioid subtype. As an extreme
example, WT1 is an unfavourable prognostic biomarker in
the entire cohort (p ¼ 0.0017, Figure 6A) but is a favourable
prognostic biomarker for high-grade serous carcinomas (p ¼
0.0086, Figure 6B). As WT1 is expressed in 80% of high-grade
serous carcinomas but rarely in other subtypes, this negative
prognostic signiﬁcance in the entire cohort reﬂects subtype
differences in expression, with WT1 most commonly ex-
pressed in the aggressive high-grade serous subtype. Four
other biomarkers (KISS1, K-Cadherin, Mesothelin, Ki-67) that
were signiﬁcant in the entire cohort did not show signiﬁcance
in any subtype.
Ki-67 serves as an additional example, which is prognostic
in the whole cohort but not when corrected for subtype. The
median for Ki-67 labelling index in the entire cohort was
PLoS Medicine | www.plosmedicine.org December 2008 | Volume 5 | Issue 12 | e232 1752
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Paired positive and negative examples for each biomarker.
doi:10.1371/journal.pmed.0050232.g001
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Ovarian Carcinoma Subtypes Are DifferentFigure 2. Biomarker Expression Rates in the Entire Cohort by Stage
*Significant differences between categories (Fisher’s exact test).
doi:10.1371/journal.pmed.0050232.g002
Figure 3. Biomarker Expression Rates in High-Grade Serous Subtype by Stage
doi:10.1371/journal.pmed.0050232.g003
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Ovarian Carcinoma Subtypes Are Different13.0% and using this as a cut-off for high versus low Ki-67
labelling index effectively separates high-grade serous carci-
nomas from low-grade serous, endometrioid, and clear cell
carcinomas (Figure 5). Mucinous carcinomas showed an
intermediate Ki-67 labelling index. Associated with high-
grade serous subtype, it is not surprising that Ki-67 has
prognostic relevance in the whole cohort (p ¼ 0.0062). When
using the subtype speciﬁc median for separate analysis of
each subtype however, Ki-67 labelling index was not of
prognostic signiﬁcance in any of the subtypes but Ki-67
labelling index was different between subtypes.
Discussion
Ovarian carcinomas subtypes are associated with distinct
genetic risk factors, underlying molecular events during
oncogenesis, stage at diagnosis, and responses to chemo-
therapy. With slight modiﬁcation of the WHO criteria for
histopathological assignment for subtype we have recently
shown that classiﬁcation of ovarian carcinomas into ﬁve
subtypes (high-grade serous, low-grade serous, clear cell,
endometrioid, and mucinous) is reproducible and is sup-
ported by biomarker expression data [5].
By demonstrating that biomarker correlations with stage or
prognosis can be explained by variations in expression rates
between subtypes, our study offers persuasive evidence
supporting the view that ovarian carcinoma subtypes are
different diseases. Biomarker expression is stable across stage
within a given subtype. Furthermore, differences in the
expression proﬁle between subtypes confound survival
analysis for biomarkers, when multiple ovarian carcinoma
subtypes are considered together. Collectively, these data
have implications for ovarian carcinoma research and treat-
ment.
Cancer treatment in general is beginning to move towards
therapies tailored for speciﬁc cancer subtypes (e.g., breast
carcinoma and lymphoma [24,25]), and this subtype speciﬁc
approach to treatment has implications for the design of
clinical trials for women with ovarian carcinomas. It has been
recognized for some time that certain ovarian carcinoma
subtypes are less sensitive to platinum-based chemotherapy
Figure 4. Biomarker Expression Rates in the Entire Cohort by Subtype
*Significant differences between categories (Fisher’s exact test). Note that the order in which biomarkers are presented is based on percentage of
positivity and that therefore the order is different in Figures 2–4.
doi:10.1371/journal.pmed.0050232.g004
Figure 5. Distribution of Ki-67 Labelling Index across Subtypes
doi:10.1371/journal.pmed.0050232.g005
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Ovarian Carcinoma Subtypes Are Differentthan the most common high-grade serous carcinomas. The
clear cell and mucinous subtypes, in particular, are candi-
dates for clinical trials to identify more active therapy than
what is currently used [9]. Given the dramatic differences in
biomarker expression between ovarian carcinoma subtypes,
our analysis suggests that advancing our understanding of
these poorly understood subtypes—including identiﬁcation
of potential therapeutic targets—will only come through
studies focusing on these speciﬁc subtypes rather than studies
of unselected series of patients.
The biomarker expression proﬁle within a given subtype is
consistent across stage. Hence, early and advanced stage
ovarian carcinomas differ primarily based on subtype, while
within a subtype there is no difference between early and
advanced stage tumors. This distinction has implications for
the research on biomarkers for ovarian carcinoma screening,
where the goal is detection of early stage disease, which has a
much greater likelihood of cure. If subtypes are neglected, a
screening marker identiﬁed in advanced stage tumors (i.e.,
high-grade serous carcinomas), may not be expressed in most
nonserous early stage ovarian carcinomas, and vice versa. For
example, CA125 is expressed in most high-grade serous
carcinoma, but only in 60% of mucinous and clear cell
subtypes, a ﬁnding that is consistent with previous studies
[26]. A related observation is that serum CA125 levels are
elevated in 80% of patients with advanced stage epithelial
ovarian carcinoma but are increased in only 60% of patients
with early stage disease [27,28]. It is likely that a panel of
tumor markers will be required to detect all subtypes. As the
biomarker expression was consistent between stages within
the subtypes, these data support the use of late stage cancers
to identify biomarkers for the early detection of cancers of
the same subtype.
Biomarker correlation with prognosis can be confounded
by subtype differences in biomarker expression. Some
biomarkers show prognostic signiﬁcance independent from
subtype, e.g., we conﬁrmed that MMP7 expression is a strong
independent prognostic factor for favourable prognosis in
the entire cohort, as shown previously [29] as well as for high-
grade serous and endometrioid subtypes. This result is the
exception rather than the rule as for most of the biomarkers,
the correlation with prognosis in the entire cohort is due to
the correlation with the most common subtype (high-grade
serous carcinoma), which in turn is associated with a poor
prognosis. The biomarkers that were of prognostic signiﬁ-
cance in subtype analysis were typically only of prognostic
value for a single subtype. WT1 is a widely used diagnostic
marker for the serous subtype [30] and is an example for how
analysis of the entire cohort can give misleading results. In
the entire cohort WT1 is an unfavourable prognostic marker
but is a favourable prognostic marker for high-grade serous
tumors (Figure 6). This latter observation may be because
WT1 is a marker for serous differentiation, and less differ-
entiated high-grade serous cancers are both less likely to
express WT1 and have a worse prognosis. This inverse
association in a subgroup, also known as Simpson’s paradox,
will not typically be revealed by multivariable analysis [19].
Another example is Ki-67; there are conﬂicting results on
the prognostic value of Ki-67 in ovarian carcinoma [31–36].
After applying a single cut-off point on the entire cohort for
identiﬁcation of Ki-67 high and Ki-67 low cases, high Ki-67
index is associated with an unfavourable prognosis. But
differences in Ki-67 indices between subtypes again confound
the analysis because nearly all high-grade serous carcinomas
have a high Ki-67 index. In analysis by subtype, Ki-67 is not of
prognostic signiﬁcance; the effect seen in the entire cohort
reﬂects an association with the high-grade serous subtype.
Adjustment for multiple comparisons is an important
consideration. However, there are several bodies of data
under discussion in different sections of this report, with
differing numbers of comparisons. For example, assessing the
proportion of positive cases across histological subtypes for
each biomarker involves the assessment of 21 tests; whereas
assessing survival within FIGO and histological subtype
groups involves more tests. Since p-value adjustment for
multiple testing uses the number of tests under consider-
ation, several collections of adjusted p-values would have to
be constructed yielding a complex distraction from the
discussion at hand. We note that for the assessment of
proportion of positive cases, the Bonferroni-adjusted level of
signiﬁcance would be 0.05/21¼0.0024, and several p-values in
that analysis are less than this level. We report raw p-values so
Figure 6. Prognostic Associations of WT1
Kaplan-Meier survival analysis of DSS.
(A) Entire cohort grouped by WT1 positive versus negative cases (p ¼ 0.0017, univariable COX regression).
(B) high-grade serous subtype grouped by WT1 positive versus negative cases (p ¼ 0.0086, univariable COX regression).
doi:10.1371/journal.pmed.0050232.g006
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Ovarian Carcinoma Subtypes Are Differentthat the reader can apply multiple comparison adjustments
relevant to the size of comparisons being made in any section
of the paper, and in future meta-analyses of subsets of these
data. Corrections for multiple comparisons were not used
because this issue of prognostic signiﬁcance is not the central
theme of the manuscript. Prognostic signiﬁcance is used to
illustrate the importance of subtype-speciﬁc analysis. A
limitation of our study is that it is performed retrospectively
[37], and 94% of patients received adjuvant platinum-based
chemotherapy. Hence, we can not adhere to the strict
deﬁnition of a prognostic marker as applying only to the
natural history of the disease.
We hope these data will end the lumping of ovarian
carcinoma subtypes within biomarker studies, as is the
current practice [38–41]. This biomarker panel shows that
subtypes have distinct expression proﬁles. One of the reasons
why no ovarian carcinoma tissue-based prognostic markers
are used clinically, despite a voluminous literature suggesting
many candidates, is that prognostic effects have proven
difﬁcult to validate. In addition to assay speciﬁc challenges,
the different frequencies of subtypes within cohorts can vary
or, as shown here with WT1, reverse prognostic effects. If
ovarian carcinoma cases are not separated by subtype or
evaluated using a stratiﬁed analysis or a model with complex
interaction terms, even a multivariable model can conceal
important ﬁndings or lead to misleading conclusions (Table
S4). The discovery, development, and validation of subtype
speciﬁc ovarian carcinoma biomarkers will require ad-
equately powered and expertly subtyped cohorts of cases.
For the rarer subtypes, the development of such research
resources will likely prove difﬁcult outside of large scale
collaborative initiatives. In order to facilitate the shift to
subtype speciﬁc management of ovarian carcinoma, subtypes
should be considered as distinct diseases in biomarker studies
and clinical trials.
Supporting Information
Figure S1. Kaplan-Meier Survival Analysis of Disease-Speciﬁc
Survival in the Entire Cohort, Stage Subgroups, Subtypes, and the
Stage Subgroups by Subtype
p-Values (Wald) were generated using a multivariable Cox regression
model including the biomarker and age. ‘‘Marker * CellType Xn p’’-
value assesses differential biomarker prognostic value in the different
subtypes (a large p-value indicates that biomarker prognosis is similar
in the subgroups, a small p-value indicates that biomarker prognosis
differs in the subgroups); ‘‘Marker * FIGO Xn p’’-value assesses
differential biomarker prognostic value in the different subgroups.
HG-SC, high-grade serous; EC, endometrioid; CC, clear cell;
FIGO¼stg12, FIGO stage I and II; FIGO¼stg3, FIGO stage III.
Found at doi:10.1371/journal.pmed.0050232.sg001 (2 MB PDF).
Table S1. Deﬁnition of Positive Staining
Found at doi:10.1371/journal.pmed.0050232.st001 (42 KB DOC).
Table S2. Biomarker Expression Rate Across Stage, Subtype, and
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Found at doi:10.1371/journal.pmed.0050232.st002 (133 KB DOC).
Table S3. Multivariable COX Proportional Hazards Including Stage,
Subtype, and Age for the Entire Cohort
Found at doi:10.1371/journal.pmed.0050232.st003 (30 KB DOC).
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Ovarian Carcinoma Subtypes Are DifferentEditors’ Summary
Background. Every year, about 200,000 women develop ovarian cancer
and more than 100,000 die from the disease. Ovarian epithelial cancer
(carcinoma) occurs when epithelial cells from the ovary or fallopian tube
acquire mutations or equivalent changes that allow them to grow
uncontrollably within one of the ovaries (two small organs in the pelvis
that produce eggs) and acquire the potential to spread around the body
(metastasize). While the cancer is confined to the ovaries, cancer
specialists call this stage I disease; 70%–80% of women diagnosed with
stage I ovarian cancer survive for at least 5 y. However, only a fifth of
ovarian cancers are diagnosed at this stage; in the majority of patients
the cancer has spread into the pelvis (stage II disease), into the peritoneal
cavity (the space around the gut, stomach, and liver; stage III disease), or
metastasized to distant organs such as brain (stage IV disease). This
peritoneal spread might be associated with often only vague abdominal
pain and mild digestive disturbances. Patients with advanced-stage
ovarian carcinoma are treated with a combination of surgery and
chemotherapy but, despite recent advances in treatment, only 15% of
women diagnosed with stage IV disease survive for 5 y.
Why Was This Study Done? Although it is usually regarded as a single
disease, there are actually several distinct subtypes of ovarian carcinoma.
These are classified according to their microscopic appearance as high-
grade serous, low-grade serous, clear cell, endometrioid, and mucinous
ovarian carcinomas. These subtypes develop differently and respond
differently to chemotherapy. Yet scientists studying ovarian carcinoma
usually regard this cancer as a single entity, and current treatment
protocols for the disease are not subtype specific. Might better progress
be made toward understanding ovarian carcinoma and toward improv-
ing its treatment if each subtype were treated as a separate disease? Why
are some tumors confined to the ovary, whereas the majority spread
beyond the ovary at time of diagnosis? In this study, the researchers
address these questions by asking whether correlations between the
expression of ‘‘biomarkers’’ (molecules made by cancer cells that can be
used to detect tumors and to monitor treatment effectiveness) and the
stage at diagnosis or length of survival can be explained by differential
biomarker expression between different subtypes of ovarian carcinoma.
They also address the question of whether early stage and late stage
ovarian carcinomas are fundamentally different.
What Did the Researchers Do and Find? The researchers measured the
expression of 21 candidate protein biomarkers in 500 ovarian carcinoma
samples collected in British Columbia, Canada, between 1984 and 2000.
For 20 of the biomarkers, the fraction of tumors expressing the
biomarker varied significantly between ovarian carcinoma subtypes.
Considering all the tumors together, ten biomarkers had different
expression levels in early and late stage tumors. However, when each
subtype was considered separately, the expression of none of the
biomarkers varied with stage. When the researchers asked whether the
expression of any of the biomarkers correlated with survival times, they
found that nine biomarkers were unfavorable indicators of outcome
when all the tumors were considered together. That is, women whose
tumors expressed any of these biomarkers had a higher risk of dying
from ovarian cancer than women whose tumors did not express these
biomarkers. However, only three biomarkers were unfavorable indicators
for high-grade serous carcinomas considered alone and the expression
of a biomarker called WT1 in this subtype of ovarian carcinoma is
associated with a lower risk of dying. Similarly, expression of the
biomarker Ki-67 was an unfavorable prognostic indicator when all the
tumors were considered, but was not a prognostic indicator for any
individual subtype.
What Do These Findings Mean? These and other findings indicate that
biomarker expression is more strongly associated with ovarian carcinoma
subtype than with stage. In other words, biomarker expression is
constant from early to late stage, but only within a given subtype.
Second, the association of biomarker expression with survival varies
between subtypes, hence lumping all subtypes together can yield
misleading results. Although these findings need confirming in more
tumor samples, they support the view that ovarian carcinoma subtypes
are different diseases. In practical terms, therefore, these findings
suggest that better ways to detect and treat ovarian cancer are more
likely to be found if future biomarker studies and clinical research studies
investigate each subtype of ovarian carcinoma separately rather than
grouping them all together.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050232.
  The US National Cancer Institute provides a brief description of what
cancer is and how it develops and information on all aspects of
ovarian cancer for patients and professionals. It also provides a fact
sheet on tumor markers (in English and Spanish)
  The UK charity Cancerbackup provides general information about
cancer and more specific information about ovarian cancer, including
tumor staging
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